BerGenBio ASA (0RU5.L)
NOK 9.0
(-0.03%)
NOK 9.0
(-0.03%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -225.1 Million | -288.23 Million | -303.34 Million | -234.29 Million | -184.14 Million | -186.7 Million |
| Net Income | -190.4 Million | -302.12 Million | -309.36 Million | -257.02 Million | -199.27 Million | -191.74 Million |
| Depreciation & Amortization | 223 Thousand | 883 Thousand | 1.31 Million | 726 Thousand | 785 Thousand | 204 Thousand |
| Deferred income taxes | - | - | 668 Thousand | 709 Thousand | 10.41 Million | - |
| Stock-based compensation | 3.13 Million | 3.46 Million | 7.11 Million | 7.41 Million | 3.84 Million | 1.67 Million |
| Change in working capital | -33.38 Million | 9.21 Million | 61 Thousand | 17.5 Million | 10.5 Million | 3.15 Million |
| Other non-cash items | -3.05 Million | 332 Thousand | -3.13 Million | -3.61 Million | -10.41 Million | 1000.00 |
| Investing Cash Flow | 3.05 Million | 3.24 Million | 3.13 Million | 3.54 Million | - | -228 Thousand |
| Investments in PPE | - | - | - | -67 Thousand | - | -228 Thousand |
| Acquisitions | - | 299 Thousand | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | 3.05 Million | 2.94 Million | - | 3.61 Million | - | - |
| Financing Cash Flow | 224.88 Million | 2.9 Million | 15.99 Million | 699.5 Million | 77.31 Million | 176.99 Million |
| Debt repayment | -193 Thousand | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 262.04 Million | 3.21 Million | 16.62 Million | 740.85 Million | 82.78 Million | 190.52 Million |
| Other Financing Activities | -37.16 Million | -314 Thousand | -634 Thousand | -41.34 Million | -5.46 Million | -13.52 Million |
| Accounts receivables | -1.62 Million | -3.46 Million | 1.83 Million | 1.59 Million | 2.01 Million | -4.4 Million |
| Accounts payables | -31.8 Million | 13.64 Million | 3.27 Million | 11.98 Million | 11.15 Million | 5.84 Million |
| Inventory | - | - | - | - | - | - |
| Other working capital | -31.76 Million | -969 Thousand | -5.03 Million | 3.93 Million | -2.65 Million | - |
| Cash at beginning of period | 150.8 Million | 436.64 Million | 721.64 Million | 253.58 Million | 360.41 Million | 370.35 Million |
| Cash at end of period | 156.42 Million | 150.8 Million | 436.64 Million | 721.64 Million | 253.58 Million | 360.41 Million |
| Capital Expenditure | - | - | - | -67 Thousand | - | -228 Thousand |
| Effect of forex changes on cash | 2.78 Million | -3.76 Million | -779 Thousand | -710 Thousand | - | - |
| Net cash flow / Change in cash | 5.61 Million | -285.84 Million | -284.99 Million | 468.05 Million | -106.82 Million | -9.93 Million |
| Free Cash Flow | -225.1 Million | -288.23 Million | -303.34 Million | -234.35 Million | -184.14 Million | -186.93 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -49.72 Million | -36.11 Million | -41.63 Million | -190.4 Million | -27.93 Million | -48.83 Million |
| Depreciation & Amortization | 105 Thousand | 105 Thousand | 101 Thousand | 223 Thousand | 109 Thousand | 7000.00 |
| Deferred income taxes | - | - | - | - | - | 2.12 Million |
| Stock-based compensation | 1.77 Million | 1.69 Million | 538 Thousand | 3.13 Million | 829 Thousand | 198 Thousand |
| Change in working capital | 825 Thousand | -5.04 Million | 20.79 Million | -33.38 Million | -29.8 Million | -16.72 Million |
| Other non-cash items | 1.52 Million | 3.71 Million | -2.69 Million | -3.05 Million | 1.45 Million | -70 Thousand |
| Investing Cash Flow | -1000.00 | 167 Thousand | 2.69 Million | 3.05 Million | - | 70 Thousand |
| Investments in PPE | 46.65 Million | - | - | - | - | - |
| Acquisitions | - | 167 Thousand | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | 19 Thousand | - | - | - | - | - |
| Financing Cash Flow | 129.83 Million | -102 Thousand | 7.57 Million | 224.88 Million | -96 Thousand | 217.4 Million |
| Debt repayment | -104 Thousand | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 129.94 Million | - | 8.86 Million | 262.04 Million | - | 253.18 Million |
| Other Financing Activities | 129.94 Million | - | - | - | - | -35.78 Million |
| Accounts receivables | -371 Thousand | -444 Thousand | 669 Thousand | -1.62 Million | -3.71 Million | -1.84 Million |
| Accounts payables | 1.19 Million | -4.6 Million | 20.08 Million | -31.8 Million | -26.09 Million | -14.87 Million |
| Inventory | - | - | - | - | - | - |
| Other working capital | 1.19 Million | - | - | - | - | - |
| Cash at beginning of period | 117.34 Million | 156.42 Million | 169.31 Million | 150.8 Million | 225.98 Million | 72.99 Million |
| Cash at end of period | 200.11 Million | 117.34 Million | 156.42 Million | 156.42 Million | 169.31 Million | 225.98 Million |
| Capital Expenditure | 46.65 Million | - | - | - | - | - |
| Effect of forex changes on cash | -416 Thousand | 3.45 Million | -1.05 Million | 2.78 Million | -1.22 Million | -1.19 Million |
| Net cash flow / Change in cash | 82.77 Million | -39.07 Million | -12.89 Million | 5.61 Million | -56.66 Million | 152.98 Million |
| Free Cash Flow | - | -42.59 Million | -22.1 Million | -225.1 Million | -55.34 Million | -63.29 Million |
BWEFF
600117
ANSALAPI
CADE
6361
CXXIF